DETECT – From Awareness to Action: Driving Multidisciplinary Application of Screening and Disease Modifying Therapies in Early Stage T1D
PATIENT CAREGIVER PERSPECTIVE PRESENTER
Mrs. Amanda Troutman
Mooresville, NC
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. This episode features a conversation with Mrs. Amanda Troutman, whose son was screened for and diagnosed with stage 2 T1D and later treated with the disease-modifying treatment, teplizumab. Amanda recounts her family’s experience with the screening and treatment process and offers insights that can influence the care of patients with or at risk for developing T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Mrs. Amanda Troutman | Has received fees for non CME services with Sanofi |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: June 20, 2025
EXPIRATION DATE: June 20, 2026
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES
Outpatient Certified Diabetes Care and Education Specialist
University of Chicago Kovler Diabetes Center
Chicago, IL
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. In this episode, Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, helps clinicians to identify individuals at greater risk for developing T1D and should, therefore, be screened for the presence of islet autoantibodies. She discusses how patients diagnosed with Stage 2 T1D might be eligible for disease-modifying therapy to delay progression to Stage 3 T1D as well as tips and resources available for both clinicians and patients that will aid them in managing T1D successfully.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions
- Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Amy Hess-Fischl MS, RDN, LDN, BC-ADM, CDCES | Speakers Bureau for Abbott Diabetes Care, Insulet, Sanofi, Xeris |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: July 25, 2025
EXPIRATION DATE: July 25, 2026
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Lucia M. Novak, MSN, ANP-BC, BC-ADM
President, Diabesity, LLC, North Bethesda, MD
Co-executive Director, Capital Health, and Metabolic Center
Capital Diabetes and Endocrine Associates
Silver Spring and Camp Springs, Maryland
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. In the third episode of the series, Lucia M. Novak, MSN, ANP-BC, BC-ADM, offers tips and strategies to help identify individuals who are at the greatest risk for developing T1D and should, therefore, be screened for the presence of islet autoantibodies. Ms. Novak also offers ways in which Certified Diabetes Care and Education Specialists serve as crucial members of the healthcare team in screening for and treating T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Develop workflows to appropriately monitor, follow-up, or refer individuals who are screening for T1D
- Develop strategies for establishing referral pathways and enhancing collaboration with specialists in order to enable earlier application of disease-modifying therapies for early stage T1D
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Lucia M. Novak, MSN, ANP-BC, BC-ADM | Receives consulting fees from Ascencia & is on the speaker’s bureau for Abbott, Novo Nordisk, Sanofi, Nestle |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: August 27, 2025
EXPIRATION DATE: August 27, 2026
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES
VP, Medical Affairs
Breakthrough T1D
Gainesville, FL
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. In the fourth episode of the series, Anastasia Albanese-O’Neill, PhD, APRN, CDCES, discusses the importance of screening for T1D and offers some of the many resources available to clinicians to help them incorporate screening into routine practice.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions.
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES | Receives consulting fees paid to Breakthrough T1D (not AAO) from Sanofi, Vertex, and Roche/Genentech. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: September 25, 2025
EXPIRATION DATE: September 25, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Rachael Sood, RN, MSN, APRN, NP-C, CDCES
Chief Executive Officer
The Diabetes Collective Mandeville, Louisiana
Patient Perspective
Katherine Ibarra
River Ridge, Louisiana
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. In the fifth episode of the series, Rachael Sood RN, MSN, NP-C, CDCES, has a candid conversation with her patient, Katie, who is living with T1D. Katie and Rachael recount how screening for T1D allowed a twisted journey of misdiagnosis and red flags reach a destination of accurate diagnosis and proper management.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
- Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Rachael Sood, RN, MSN, APRN, NP-C, CDCES | Receives consulting fees from Sanofi Pharmaceutical Educational T1d speaking/dinner – presentations. 2023 to present. Is on the speakers bureau for Dexcom Speakers Bureau (2023 – to current) Sanofi – T1d – Social Media influencer Summit. Fees for Non-CME/CE Services Received Directly from a Commercial Interest or its Agent from Eli Lilly Cardio Metabolic Faculty – Speakers Bureau CCS Medical – DME – Sales force presentation. other paid partners: Twiist – Sequel Med Tech – product theatre 2024 Dexcom by Stelo- Podcast and Blogging 2024 to current. Baqsimi – consulting/product theatre – 2024 ADCES – Louisiana southern region – CME – Diabetes and CDCES updates for 2024 – 2025 -dinner meeting/speaking. Consultant 360 – CGM- biosensor – webinar discussion March 2025 sponsored in part by Dexcom CPT (certified pump trainer) for Tandem Diabetes 2024 to current. CPT (certified pump trainer) for Insulet – Omnipod 2024 to current CPT (certified pump trainer) for iLet by Beta Bionics 2024 – to current |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: October 15, 2025
EXPIRATION DATE: October 15, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Roshanak Monzavi, MD
Clinical Professor of Pediatrics
Director of Pediatric Endocrinology Fellowship Program
Center for Endocrinology, Diabetes, and Metabolism
Children’s Hospital Los Angeles
Los Angeles, California
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Irvine, California
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. In the sixth episode of the series, two experts in diabetes care and management Roshanak Monzavi and Chuck Vega discuss ways in which busy clinicians can incorporate screening for T1D and identify which patients might be eligible for treatment with disease-modifying therapy.
TARGET AUDIENCE
This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Develop workflows to appropriately monitor, follow-up, or refer individuals who are screened for T1D.
- Develop strategies for establishing referral pathways and enhancing collaboration with specialists in order to enable earlier application of disease-modifying therapies for early stage T1D.
- Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Roshanak Monzavi, MD | Has nothing to disclose. |
| Charles Vega, MD, FAAFP | Consulting fee: Boehringer Ingelheim and Exact Sciences |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
- Melanie Grau, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: November 17, 2025
EXPIRATION DATE: November 17, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Jacqueline McManemin, RN, BSN, CDCES
Nurse Manager
School Health Division
Chair and Board Member
Virginia Diabetes Council
Springfield, Virginia
PROGRAM OVERVIEW
This DETECT T1D podcast series is designed to educate multidisciplinary clinicians on the practical aspects of type 1 diabetes (T1D) screening, follow-up procedures, early referral, and administration of disease-modifying therapies. In this final episode, Jacqueline McManemin, RN, discusses the critical role of school nurses in T1D screening.
TARGET AUDIENCE
This activity is intended for multidisciplinary clinicians who refer, treat or care for patients with or at high risk for T1D, including primary care providers, pediatricians, pediatric and adult endocrinologists, diabetes educators, infusion professionals, school nurses, and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.25 ANCC contact hour.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 CPEU.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Jacqueline McManemin, RN, BSN, CDCES | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Melissa Carter, MS, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Naomi De Brito, Program Manager for Med Learning Group, has nothing to disclose.
- Melanie Grau, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Please listen to the podcast below:
RELEASED DATE: December 17, 2025
EXPIRATION DATE: December 17, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
